Cancer that originates in the lymph nodes is called lymphoma. The name covers a broad family of cancers that arise when white blood cells called lymphocytes, which normally help your body fight infections, begin growing out of control within the lymphatic system. Lymphoma is not a single disease but rather dozens of subtypes grouped under two major umbrellas, Hodgkin lymphoma and non-Hodgkin lymphoma, each with distinct biology, behavior, and treatment strategies.
Lymphoma Versus Cancer That Has Spread to Lymph Nodes
One of the most common points of confusion is the difference between lymphoma and metastatic cancer found in a lymph node. If you have breast cancer, lung cancer, or thyroid cancer and it spreads to nearby lymph nodes, those nodes now contain metastatic cancer cells, not lymphoma. The cancer cells in that situation still look and behave like the organ they came from. In lymphoma, the cancer starts in the lymphocytes themselves. The distinction matters because the two conditions are treated very differently. Metastatic cancer in a lymph node is staged and managed as part of the original cancer, while lymphoma has its own classification and therapy protocols.
The physical differences run deep. In metastatic lymph nodes, the outer layer thickens and stiffens because invading cancer cells produce fibrous tissue and sometimes calcifications. Lymphoma nodes, on the other hand, are packed with rapidly multiplying lymphocytes without much of that fibrous reaction, which gives them a different texture on imaging and during examination.1PubMed Central. Differentiating cervical metastatic lymphadenopathy and lymphoma by shear wave elastography This is one reason doctors use specialized ultrasound techniques alongside biopsies when evaluating a suspicious lymph node.
Hodgkin Lymphoma and Non-Hodgkin Lymphoma
The two main categories of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is identified by the presence of distinctive giant cells called Reed-Sternberg cells, which are abnormal B lymphocytes surrounded by a characteristic mix of immune cells.2PubMed Central. Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma In about 86% of classical Hodgkin lymphoma cases, these Reed-Sternberg cells express a signaling protein called interleukin-13, a marker that is largely absent in non-Hodgkin subtypes and helps pathologists tell the two apart.3PubMed. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
Non-Hodgkin lymphoma is far more common and includes a wide range of subtypes. These can arise from B cells, T cells, or natural killer cells. T-cell and NK-cell lymphomas, for example, come from either immature T cells or from mature T and NK cells.4Blood. A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas Where the cancer sets up shop often depends on the cell of origin. Lymphomas from T cells of the adaptive immune system tend to stay within lymph nodes and blood, while those derived from the innate immune system are more likely to appear outside the nodes entirely, in sites like the skin, gut, or nasal passages.5PubMed Central. Pathobiology of T-cell and NK-cell lymphomas
Cells resembling Reed-Sternberg cells can occasionally show up in non-Hodgkin lymphomas, which creates a diagnostic challenge. These look-alikes share many of the same surface markers as the real thing, but the surrounding cellular environment is different. Because Hodgkin and non-Hodgkin lymphomas call for different treatments, getting the distinction right is critical.2PubMed Central. Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma
Indolent Versus Aggressive Subtypes
Within non-Hodgkin lymphoma, subtypes are broadly classified as indolent (slow-growing) or aggressive (fast-growing), and the difference affects both urgency and curability in surprising ways. Aggressive non-Hodgkin lymphomas, such as diffuse large B-cell lymphoma, grow quickly and usually require immediate chemotherapy, but many patients can be cured. Indolent non-Hodgkin lymphomas, such as follicular lymphoma, follow a chronic course with repeated relapses and progression over years, often without a definitive cure.6Blood. Quality of Life in Non-Hodgkin Lymphoma: A Comparison Between Survivors of Indolent and Aggressive Disease That counterintuitive pattern, where the slower cancer is harder to eliminate permanently, catches many people off guard.
In indolent cases, doctors sometimes recommend a strategy called “watchful waiting,” where treatment is deferred until the disease causes symptoms or shows signs of progression. When treatment is needed, first-line options often combine chemotherapy with an antibody drug targeting the lymphoma cells.7PubMed. Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin’s lymphoma
When Lymphoma Shows Up Outside the Lymph Nodes
Roughly 30% of lymphomas occur outside the lymph nodes, spleen, or bone marrow, and the rate of these extranodal lymphomas has been rising.8PubMed Central. Extranodal lymphoma: pathogenesis, diagnosis and treatment Common sites include the stomach, skin, central nervous system, and lungs. The fact that a cancer can be called lymphoma even when it is not in a lymph node confuses many people, but the name refers to the cell of origin (lymphocytes), not the location. Stomach lymphoma, for instance, is still lymphoma because the cancerous cells are lymphocytes that happened to reside in the stomach lining.
What Raises the Risk of Lymphoma
Lymphoma has no single cause, but several factors push the risk upward. Viral infections, immune system dysfunction, autoimmune disease, and certain environmental exposures all play documented roles.
Viral Connections
Epstein-Barr virus, the pathogen behind infectious mononucleosis, infects more than 90% of adults worldwide, usually without consequence.9PubMed Central. How Epstein Barr Virus Causes Lymphomas In rare cases, the virus can drive the development of several lymphoma types, including Burkitt lymphoma and certain Hodgkin lymphoma subtypes.10PubMed Central. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence People who have had infectious mononucleosis carry about four times the usual risk of developing EBV-positive Hodgkin lymphoma later in life.11PubMed. Characteristics of Hodgkin’s lymphoma after infectious mononucleosis That does not mean that mono leads to lymphoma often; the absolute risk remains low. But it illustrates how a common virus can set the stage for cancer in a small number of people.
Autoimmune Disease
People with autoimmune diseases face a notably higher lymphoma risk. Across a large-scale study, autoimmune conditions roughly doubled the incidence of lymphoma compared to people without autoimmune disease. Among 23 autoimmune conditions studied, 14 showed significantly elevated risk, with some rare conditions like Takayasu arteritis carrying particularly high hazard ratios. The use of two or more immunosuppressive medications further amplified the risk.12Blood Cancer Journal. Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study Sjögren’s disease stands out especially, with a reported standardized incidence ratio as high as 18.8 for lymphoma.13PubMed Central. Autoimmune disease-associated lymphomas: research progress and review The relationship appears to be bidirectional: the chronic immune stimulation from autoimmune disease promotes lymphocyte proliferation, while the treatments used to suppress that immune response can independently raise lymphoma risk.
Pesticide Exposure
Occupational exposure to certain agricultural chemicals has been linked to non-Hodgkin lymphoma. A systematic review and meta-analysis found positive associations between NHL and phenoxy herbicides, carbamate insecticides, organophosphorus insecticides, and the organochlorine insecticide lindane. The herbicide glyphosate was specifically associated with B-cell lymphoma, and phenoxy herbicide exposure was linked to diffuse large B-cell lymphoma.14PubMed Central. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis These findings generally apply to people with sustained occupational exposure rather than occasional household use.
How Lymphoma Is Diagnosed
Swollen lymph nodes are the most recognizable symptom, but most swollen nodes are caused by infections and other benign processes, not cancer. That overlap is exactly what makes diagnosis tricky. Ultrasound with color Doppler can help distinguish between metastatic nodes, lymphoma, and benign swelling based on blood flow patterns and node shape.15PubMed. Color/power Doppler sonographic differential diagnosis of superficial lymphadenopathy: metastasis, malignant lymphoma, and benign process But imaging alone is rarely definitive.
Biopsy is the gold standard. Excisional biopsy, where an entire lymph node is removed and examined, provides the best tissue architecture for pathologists to work with. Core needle biopsy is sometimes used as an alternative, though guidelines emphasize the importance of supplementing it with additional testing such as flow cytometry to avoid compromising diagnostic accuracy.16PubMed. Diagnosing Lymphoproliferative Disorders Using Core Needle Biopsy Versus Surgical Excisional Biopsy: Three-Year Experience of a Reference Center in Lebanon Flow cytometry, which identifies the specific surface markers on cells drawn from the node, can closely mirror the results obtained from surgical excision when performed correctly on fine-needle aspirate samples.17PubMed Central. Flow immunophenotyping of benign lymph nodes sampled by FNA: Representative with diagnostic pitfalls
Gene expression profiling has also shown the ability to distinguish lymphoma from reactive (non-cancerous) lymph node swelling and to classify the major subtypes in a single test.18PubMed Central. Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling This technology is not yet standard everywhere but represents a direction that could simplify diagnosis in the future.
Staging and Monitoring
Once lymphoma is confirmed, doctors need to determine how far it has spread. The current standard is the Lugano classification, which incorporates PET-CT scanning into staging and response assessment. PET-CT works by detecting areas of high metabolic activity, which light up where cancer cells are actively dividing. This approach has been shown to predict outcomes effectively across a range of lymphoma subtypes, and it is used both at diagnosis and during treatment to gauge whether therapy is working.19PubMed Central. Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT
Staging runs from stage I (lymphoma in a single node region) through stage IV (widespread disease involving organs outside the lymphatic system). The stage at diagnosis influences treatment intensity, but in lymphoma more than many other cancers, the specific subtype often matters as much as, or more than, the stage. A stage IV indolent follicular lymphoma might be watched without treatment, while a stage I aggressive diffuse large B-cell lymphoma would typically receive chemotherapy right away.
How Lymphoma Hides from Your Immune System
One of the more fascinating aspects of lymphoma biology is the way these cancers manipulate the very immune system they arose from. Lymphoma cells interact with surrounding non-cancerous cells to build an immunosuppressive neighborhood. The resulting dysfunction among immune cells does not just allow the cancer to grow passively; the tumor can become actively dependent on growth signals provided by its hijacked neighbors.20PubMed Central. Lymphoma: immune evasion strategies In follicular lymphoma, for instance, the tumor microenvironment is enriched with exhausted killer T cells, regulatory T cells that suppress immune attacks, and macrophages that paradoxically help the cancer survive through sustained signaling.21PubMed. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm
Lymphoma cells also use strategies such as reducing the surface markers that would flag them for immune destruction, or secreting chemicals that dampen the activity of nearby immune cells.22Haematologica. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy Understanding these evasion tactics is what drove the development of immunotherapy approaches that aim to strip away the tumor’s defenses rather than just poisoning the cells directly.
Treatment Approaches, Including CAR-T Cell Therapy
Lymphoma treatment spans a wide range depending on the subtype, stage, and patient. Chemotherapy regimens remain the backbone for most lymphomas, often combined with monoclonal antibodies that target specific proteins on the surface of lymphoma cells. Radiation therapy plays a role in some early-stage or localized cases. For aggressive B-cell lymphomas like diffuse large B-cell lymphoma, a standard first-line regimen combines several chemotherapy drugs with an anti-CD20 antibody.
For patients whose lymphoma comes back after initial treatment or does not respond to it, CAR-T cell therapy has become a transformative option. This approach involves removing a patient’s own T cells, genetically engineering them to recognize a protein on lymphoma cells called CD19, and infusing them back. Three CD19-targeting CAR-T products are now FDA-approved for relapsed or refractory diffuse large B-cell lymphoma. Durable remissions are seen in roughly 30% to 40% of treated patients.23PubMed Central. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma Those numbers are remarkable for a population that had already failed multiple lines of treatment, but they also mean that up to 60% of patients eventually progress or relapse after CAR-T therapy, and the reasons for that resistance are still being studied.24PubMed Central. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail? Side effects, including cytokine release syndrome and neurological toxicity, require that CAR-T treatment be administered at specialized centers.
Lymphoma in Children and Young Adults
Lymphoma does not look the same across all ages. Children and adolescents tend to develop high-grade (aggressive) subtypes such as Burkitt lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma. Low-grade subtypes like follicular lymphoma become more common with increasing age. Treatment outcomes for children with non-Hodgkin lymphoma are generally better than for adults, a difference that reflects multiple factors: children tolerate intensive chemotherapy better, their tumors often have different biological features, and psychosocial factors like adherence to treatment schedules differ as well.25PubMed Central. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum
Young adults occupy an awkward middle ground. They sometimes have tumor biology that looks more like a child’s but are treated using adult protocols, which may be less effective for their disease. Recognizing these age-related differences has led to growing interest in applying pediatric-style treatment strategies to adolescent and young adult patients.
Long-Term Risks After Lymphoma Treatment
Surviving lymphoma is not the end of the story. Long-term survivors of Hodgkin lymphoma, in particular, face an elevated risk of second cancers and cardiovascular disease for decades after treatment. Compared to the general population, Hodgkin lymphoma survivors carry a two- to fourfold increased risk of developing both second cancers and cardiovascular disease.26PubMed Central. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment Radiation therapy is associated with a 1.5- to 15-fold increased risk of solid cancers depending on the site irradiated, and chemotherapy contributes its own cardiovascular toxicity.
A large study tracking patients for a median of about 19 years found that the risk of second cancers remained elevated even 35 or more years after treatment. By 40 years, the cumulative incidence of a second cancer reached roughly 49%.27PubMed. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma These figures come from patients treated in earlier decades when radiation fields were larger and chemotherapy regimens more toxic, and modern protocols aim to reduce late effects. Still, the data underscore why survivorship care, including regular cancer screening and cardiac monitoring, is not optional for lymphoma survivors.
Dogs Get Lymphoma Too
Lymphoma is not unique to humans. Dogs develop the full spectrum of lymphoid cancers seen in people, and the similarities are striking. Canine lymphomas retain the same microscopic appearance, biological behavior, and even many of the same molecular abnormalities that drive human disease.28Veterinary Immunology and Immunopathology. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications This has made dogs exceptionally useful as models for lymphoma research. Because canine cancers develop and progress faster than their human counterparts, researchers can test new treatments and observe outcomes in a compressed timeline. The overlap also means that insights from veterinary oncology sometimes feed directly into human clinical trials, and vice versa. Certain breeds, particularly golden retrievers and boxers, are at elevated risk, suggesting a genetic component that parallels human family-clustering patterns in lymphoma.